The sequencing reagents market was valued at US$ 5,530.32 million in 2020 and is projected to reach US$ 14,195.60 million by 2028; it is expected to grow at a CAGR of 12.5% from 2020 to 2028.

Sequencing reagents are used during the process of sequencing. The use of these reagents highly depends on the desired result to be obtained. They form an essential part of the sequencing reactions, which can be used across various other applications as well. An increase in R&D activities worldwide is expected to drive the growth of the market during the forecast period.  

The sequencing reagents market is segmented on the basis of reagent type, technology, application, end user, and geography. By geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the sequencing reagents market, emphasizing on parameters such as market trends, technological advancements, and market dynamics along with the analysis of competitive landscape of world’s leading market players.    

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Sequencing Reagents Market: Strategic Insights

Market Size Value in	US$ 5.53 Billion in 2020
Market Size Value by	US$ 14.2 Billion by 2028
Growth rate	CAGR of 12.5% from 2020 to 2028
Forecast Period	2021-2028
Historic Period	2018-2019

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Market Insights

Five years ago, genomic sequencing was restricted to the research environment. Now, it is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients is expected to be generated within healthcare. Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, totaling over US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implementation and gathering evidence for broader adoption, thereby driving the market growth.
The UK has announced the world’s largest genome project as a part of 200 million public–private collaboration between charities and pharma. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as a part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from the UK health services and create new products and services that diagnose diseases earlier and more efficiently.
In November 2018, Stilla Technologies announced that it had completed a US$ 18.3 million (EUR 16 million) Series A financing round led by Illumina Ventures. The company will use the funds to commercialize its Naica digital PCR system and develop clinical applications.

In August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding, and it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company’s mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.
In April 2020, MedGenome—a Bengaluru-based genetic diagnostics, research, and data company—announced that it had raised US$ 55 million (about INR 419 crore) in a new round of funding, led by global impact investment firm LeapFrog Investments. Also, MedGenome claims to have built the largest database of South Asian genetic variants in genetic diagnostics in India and research partnerships. It has completed over 200,000 genomic tests to date and obtained samples from more than 550 hospitals and 6,000 clinicians across India.

Thus, due to the continuous funding by the manufacturers and government in the field of genomics, the sequencing reagent market is expected to witness growth during the forecast period.

Declining Cost of Sequencing Procedures Contributes Significantly to Market Growth

The cost of genome sequencing has been dropping radically, nearly a million-fold in the past six-seven years. In the recent years, next generation sequencing price have declined substantially. For instance, first whole human genome sequencing cost over US$ 3.7 billion in 2000 and took more than a decade for the completion. However, the costs for the same in recent years has reduces to US$ 1,000 and the process requires a smaller number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. The decline in the cost can be checked by the cost to sequence a genome diverging drastically around 2008, falling from approximately US$ 10 million to nearly US$ 1,000 at the present date.
Many of the testing services cost a couple hundred dollars and the lowered cost and higher speed could not only give them a larger margin in profits but the ability to process faster and possibly bring in a higher load of consumers. The latest machines offered by Illumina are lower priced devices and available in two models—NovaSeq 5000 for US$ 850,000 and the NovaSeq 6000 for US$ 985,000.
The rapid reduction in costs has now helped in clinical research, but even greater speed and a lowered price point will likely be enticing to health startups for the help of consumers. In 2003, the first sequencing of the whole human genome cost approximately US$ 2.7 billion; however, DNA sequencing company, Illumina has launched the latest and advanced machine for the whole genome sequencing, and it costs less than US$ 100. The price for genome sequencing has been in continuous free fall since the establishment. In 2006, Illumina’s first machine, which was used for the sequencing of a human genome, cost US$ 300,000, and in 2014, the company revealed that the cost of the same sequencing has been reduced to US$ 1,000. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled the cost and time reduction in the sequencing.
In 2003, the International Human Genome Sequencing Consortium started genome analysis by sequencing a complete human genome. The sequencing cost approximately US$ 2.6 billion (EUR 2.3 billion). By 2008, costs dropped to lower than US$ 1.4 million (EUR 1 million) per genome. The cost of the exome sequencing has also become cheaper. It costs US$ 400 to US$ 500 to sequence an exome, and US$ 1,000 to US$ 1,200 to sequence a genome. Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing.

Technology Insights                     

Based on technology, the global sequencing reagents market is segmented into next generation sequencing, sanger sequencing, and third generation sequencing. In 2020, the next generation sequencing segment held the largest share in the market. Moreover, the market for the same segment is expected to grow at the highest rate by 2028. Next-generation sequencing is a technique that provides massive parallel decoding of RNA or DNA fragments, based on single molecule sequencing principles or sequencing-by-synthesis. It produces the massive quantities of sequencing data, which can only be analyzed with using dedicated bioinformatics tools. This factor is likely to boost the demand for sequencing reagents across the world during the forecast period

Reagent Type Insights

Based on reagent type, the global sequencing reagents market is segmented into control kits, library kits, template kits, sequencing kits, and other reagent types. The control kits segment held the largest market share in 2020, and it is further expected to dominate the market by 2028. Quality control for cluster generation, sequencing, and alignment, as well as calibration control for cross-talk matrix generation, phasing, and prephasing are provided by control kits.

Application Insights

Based on application, the global sequencing reagents market is segmented into agrigenomics and forensics, clinical investigation, oncology, reproductive health, and other applications. The oncology segment held the largest market share in 2020, and it is further expected to dominate the market by 2028. The combination of next-generation sequencing (NGS) and bioinformatics tools has an ability to transform oncology research, diagnosis, and treatment.

End User Insights

Based on end user, the global sequencing reagents market is segmented into hospitals and clinics, research institutes, and pharmaceutical and biotechnology companies, and others. The hospitals and clinics segment held the largest market share in 2020, and it is further expected to dominate the market by 2028. Hospitals and clinics are primary contact points for patients to get their diagnosis done and opt for treatment options and alternatives.    

Product launches, and mergers and acquisitions are highly adopted strategies adopted by the players operating in the global sequencing reagents market. A few of the recent key product developments are listed below:

In April 2021, QIAGEN N.V. launched QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly reduces library turnaround times and plastics use compared with ARTIC project protocols [primer-based approaches for next-generation sequencing (NGS)].

In December 2018, Abcam plc, a global innovator in life science reagents and tools, and QIAGEN (Suzhou) Translational Medicine Co., Ltd. (QIAGEN (Suzhou)) signed a Memorandum of Understanding (MoU) agreement to jointly develop a pipeline of Companion Diagnostic (CDx) and In Vitro Diagnostic reagents and kits to meet the specific needs of the Chinese market.

The COVID-19 pandemic is having the positive impact on the sequencing reagents market. Vaccine for COVID-19 has been developed by several pharmaceutical companies and vaccination has also been started in most of the countries. The genome sequencing has increasingly become an important tool for studying disease outbreaks, which is anticipated to have a positive impact on the other segments of the market in the coming months. On the other side, disruptions in the supply chain caused due to the halt in global operations are hindering the market growth. 

Sequencing Reagents Market Report Scope

Sequencing Reagents – Market Segmentation

By Technology

• Next Generation Sequencing
• Sanger Sequencing
• Third Generation Sequencing

By Reagent Type

• Control Kits
• Library Kits
• Template Kits
• Sequencing Kits
• Other Reagent Types

By Application

• Agrigenomics and Forensics
• Clinical Investigation
• Oncology
• Reproductive Health
• Other Applications

By End User

• Hospitals and Clinics
• Research Institutes
• Pharmaceutical and Biotechnology Companies
• Other End Users

By Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

• Middle East & Africa (MEA)

  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa

• South and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• BGI Group
• F. Hoffmann-La Roche Ltd.
• Fluidigm Corporation
• Illumina, Inc.
• LGC Biosearch Technologies
• Pacific Biosciences of California, Inc.
• Qiagen
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.
• Trilink Biotechnologies